Who to call at Pasithea Therapeutics Corp., and when
Fundz watches for the moments Pasithea Therapeutics Corp. starts buying, and tells you who to reach.
- An alert the day Pasithea Therapeutics Corp. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pasithea Therapeutics Corp., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pasithea Therapeutics Corp.. With Fundz connected, it knows.
Pasithea Therapeutics Corp.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
pasitheatherapeutics.comAI Executive Summary
AI-powered analysis of 8-K filing content
Pasithea's board approved higher base salaries for CEO Dr. Tiago Reis Marques ($533,000) and CFO Daniel Schneiderman ($391,000), along with stock option grants at $0.715 per share and full vesting upon a Change in Control, despite the company's stated cash constraints. The board also adjusted director cash retainers, including a significant cut for the Board Chair, to conserve cash.
Key Takeaways
The CEO's base salary rises to $533,000 while his target bonus drops to 55% of base, and the CFO's base salary rises to $391,000 with his target bonus raised to 40%, all retroactive to January 1, 2025
The board granted options at a $0.715 exercise price (the October 24, 2025 Nasdaq close): 493,341 to the CEO, 317,266 to the CFO, and 352,266 in aggregate to certain employees.
3 more takeaways
Related Filings (7)
7 more filings from Pasithea Therapeutics Corp. in the last 90 days
Filing Overview
What This Means
Pasithea Therapeutics Corp. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.